<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZUPLENZ- ondansetronÂ film, solubleÂ </strong><br>Galena Biopharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ZUPLENZ<span class="Sup">Â®</span> safely and effectively. See full prescribing information for ZUPLENZ.<br>ZUPLENZ (ondansetron) Oral Soluble Film<br>Initial U.S. Approval: 1991
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" width="45.150%">
<col align="left" width="54.850%">
<tbody class="Headless"><tr>
<td align="left" valign="top">Warnings and Precautions, (<a href="#s27">5.3</a>)
</td>
<td align="right" valign="top">09/2014
</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ZUPLENZ is a 5-HT3 receptor antagonist indicated for:
 </p>
<ul class="Disc">
<li>Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic cancer chemotherapy. (<a href="#s3">1.1</a>)
</li>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (<a href="#s4">1.2</a>)
</li>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to abdomen, or daily fractions to the abdomen. (<a href="#s5">1.3</a>)
</li>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#s6">1.4</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic cancer chemotherapy</span>: The adult oral dosage is 24 mg given successively as three 8 mg films administered 30 minutes before the start of chemotherapy. (<a href="#s8">2.1</a>)
</li>
<li>
<span class="Bold">Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with moderately emetogenic cancer chemotherapy:</span><ul class="Circle">
<li>
<span class="Underline">Adults and pediatric patients 12 years of age and older</span>: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. (<a href="#s11">2.2</a>)
</li>
<li>
<span class="Underline">Pediatric patients 4 through 11 years of age</span>: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy. (<a href="#s11">2.2</a>)
</li>
</ul>
</li>
<li>
<span class="Bold">Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with radiotherapy:</span> The adult dosage is one 8 mg film three times a day. (<a href="#s14">2.3</a>)
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span>: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia. (<a href="#s17">2.4</a>)
</li>
<li>See dosage adjustment for patients with impaired hepatic function. (<a href="#s20">2.5</a>)
</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>4 mg and 8 mg oral soluble film. (<a href="#s22">3</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Concomitant use of apomorphine. (<a href="#s23">4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to ondansetron. (<a href="#s23">4</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, have been reported in patients who have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other selective 5-HT3 receptor antagonists. (<a href="#s25">5.1</a>)
</li>
<li>ZUPLENZ in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>. Monitor ECG in patients with electrolyte abnormalities (e.g., <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>), <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> or patients taking other medicinal products that lead to QT prolongation. (<a href="#s26">5.2</a>)
</li>
<li>The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mask a progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and/or gastric distension. (<a href="#s27">5.3</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (<a href="#s27">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li> The most common adverse drug events (â‰¥5%) in chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and radiotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#s31">6.1</a>)
</li>
<li> The most common adverse event (â‰¥5%) in <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#s31">6.1</a>)
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Galena Biopharma, Inc., Portland, OR, 97239, at 1 855 636 5710 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Apomorphine â€“ profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. Concomitant use with ondansetron is contraindicated. (<a href="#s39">7.1</a>)
</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Pediatrics:</span> The safety and effectiveness in pediatric patients have only been established for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with moderately emetogenic cancer chemotherapy in patients four years of age  and older (<a href="#s50">8.4</a>). For dosage recommendations see (<a href="#s11">2.2</a>).
</li>
<li>
<span class="Bold">Impaired Hepatic Function:</span> In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 or greater)<span class="Sup">2</span>, a total daily dose of 8 mg should not be exceeded. (<a href="#s53">8.7</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Highly Emetogenic Cancer Chemotherapy
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Moderately Emetogenic Cancer Chemotherapy
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Radiotherapy
</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Highly Emetogenic Cancer Chemotherapy
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Moderately Emetogenic Cancer Chemotherapy
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Radiotherapy
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Dosage Adjustment for Patients with Impaired Hepatic Function
</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Important Administration Instructions
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Electrocardiographic Changes
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Masking of Progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span> and/or Gastric Distension
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Effect on Peristalsis
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Apomorphine
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Phenytoin, Carbamazepine, Rifampicin
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Serotonergic Drugs
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Tramadol
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Chemotherapy
</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Temazepam
</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Antacids
</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Alfentanil and Atracurium
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</a></h1>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Radiation-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</a></h2>
<h2><a href="#section-14.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</a></h2>
<h1><a href="#section-15" class="toc">15 REFERENCES
</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Highly Emetogenic Cancer Chemotherapy
</h2>
<p class="First">ZUPLENZ (ondansetron) oral soluble film is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic cancer chemotherapy, including cisplatin â‰¥50 mg/m<span class="Sup">2
</span><span class="Italics">[see Clinical Studies, (<a href="#s74">14.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Moderately Emetogenic Cancer Chemotherapy
</h2>
<p class="First">ZUPLENZ is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of moderately emetogenic cancer chemotherapy <span class="Italics">[see Clinical Studies (<a href="#s74">14.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Radiotherapy
</h2>
<p class="First">ZUPLENZ is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen <span class="Italics">[see Clinical Studies (<a href="#s79">14.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</h2>
<p class="First">ZUPLENZ is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> will occur postoperatively. In patients where <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> must be avoided postoperatively, ZUPLENZ is recommended even where the incidence of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is low <span class="Italics">[see Clinical Studies (<a href="#s83">14.3</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Highly Emetogenic Cancer Chemotherapy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span></p>
<p>The recommended adult oral dosage of ZUPLENZ (ondansetron) oral soluble film is 24 mg given successively as three 8 mg films administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin â‰¥50  mg/m<span class="Sup">2</span>. Each ZUPLENZ oral soluble film should be allowed to dissolve completely before administering the next film <span class="Italics">[see Dosage and Administration (<a href="#s21">2.6</a></span>)]. Multiday, single-dose administration of a 24 mg dosage has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Underline">Pediatrics</span></p>
<p>Safety and effectiveness of ZUPLENZ in pediatric patients have not been established for this indication.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Moderately Emetogenic Cancer Chemotherapy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span></p>
<p>The recommended adult oral dosage is one 8 mg ZUPLENZ oral soluble film given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8 mg ZUPLENZ oral soluble film should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy <span class="Italics">[see Dosage and Administration (<a href="#s21">2.6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Underline">Pediatrics</span></p>
<p>For pediatric patients 12 years of age and older, the dosage is the same as for adults. For pediatric patients 4 through 11 years of age, the dosage is one 4 mg ZUPLENZ oral soluble film given three times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4 mg ZUPLENZ oral soluble film should be administered three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy <span class="Italics">[see Dosage and Administration (<a href="#s21">2.6</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Associated with Radiotherapy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span></p>
<p>The recommended adult oral dosage of ZUPLENZ oral soluble film is one 8 mg film given three times a day <span class="Italics">[see Dosage and Administration (<a href="#s21">2.6</a>)]</span>.
</p>
<p><span class="Italics">For total body irradiation</span>, one 8 mg ZUPLENZ oral soluble film should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
</p>
<p><span class="Italics">For single high-dose fraction radiotherapy to the abdomen</span>, one 8 mg ZUPLENZ oral soluble film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
</p>
<p><span class="Italics">For daily fractionated radiotherapy to the abdomen</span>, one 8 mg ZUPLENZ oral soluble film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Underline">Pediatrics</span></p>
<p>Safety and effectiveness of ZUPLENZ in pediatric patients have not been established for this indication.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span></p>
<p>The recommended adult oral dosage of ZUPLENZ oral soluble film is 16 mg given successively as two 8 mg films 1 hour before induction of anesthesia. Each ZUPLENZ oral soluble film should be allowed to dissolve completely before administering the next film <span class="Italics">[see Dosage and Administration (<a href="#s21">2.6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-2.4.2"></a><p></p>
<p class="First"><span class="Underline">Pediatrics</span></p>
<p>Safety and effectiveness of ZUPLENZ in pediatric patients have not been established for this indication.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Dosage Adjustment for Patients with Impaired Hepatic Function
</h2>
<p class="First">In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 or greater)<span class="Sup">2</span>, clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>)]</span>. In such patients, a total daily dose of 8 mg should not be exceeded.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Important Administration Instructions
</h2>
<p class="First">With dry hands, fold the pouch along the dotted line to expose the tear notch. While still folded, tear the pouch carefully along the edge and remove the ZUPLENZ oral soluble film from the pouch. Immediately place the film on top of the tongue where it dissolves in 4 to 20 seconds. Once the ZUPLENZ oral soluble film is dissolved, swallow with or without liquid <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>)]</span>. Wash hands after taking ZUPLENZ.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s22"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">ZUPLENZ (ondansetron) oral soluble film is available in 4 mg and 8 mg strengths. The thin white opaque films are rectangularly shaped strips with a printed identifier in black ink of â€œ4 mgâ€? for ZUPLENZ 4 mg or â€œ8 mgâ€? for ZUPLENZ 8 mg.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s23"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> when apomorphine was administered with ondansetron.
</p>
<p>ZUPLENZ (ondansetron) oral soluble film is contraindicated for patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported in patients taking ondansetron.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s24"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, have been reported in patients who have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other selective 5-HT<span class="Sub">3</span> receptor antagonists.  ZUPLENZ (ondansetron) oral soluble film should be discontinued immediately at the first sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Electrocardiographic Changes
</h2>
<p class="First">ECG changes including QT interval prolongation have been seen in patients receiving ondansetron. In addition, post-marketing cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> have been reported in patients using ondansetron. Avoid ZUPLENZ in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>. ECG monitoring is recommended in patients with electrolyte abnormalities (e.g., <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>), <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> or patients taking other medicinal products that lead to QT prolongation.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>
</h2>
<p class="First">The development of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with 5-HT3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> occurring with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of ondansetron alone has also been reported. The majority of reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> related to 5-HT3 receptor antagonist use occurred in a post anesthesia care unit or an infusion center.
</p>
<p>Symptoms associated with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may include the following combination of signs and symptoms: <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially with concomitant use of Zuplenz and other serotonergic drugs. If symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> occur, discontinue Zuplenz and initiate supportive treatment. Patients should be informed of the increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially if Zuplenz is used concomitantly with other serotonergic drugs [<span class="Italics">see Drug Interactions (<a href="#s41">7.3</a>), Overdosage (<a href="#s55">10</a>.), Patient Counseling Information (<a href="#s86">17</a>.)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Masking of Progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span> and/or Gastric Distension
</h2>
<p class="First">The use of ZUPLENZ in patients following abdominal surgery or in patients with chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mask a progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and/or gastric distension.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Effect on Peristalsis
</h2>
<p class="First">ZUPLENZ is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s30"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
</p>
<p>The following adverse events have been reported in clinical trials of patients treated with ondansetron, the active ingredient of ZUPLENZ. A causal relationship to therapy with ondansetron was unclear in many cases.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Adverse Events Reported in â‰¥5% of Adult Patients After Single Day Therapy Ondansetron HCl Tablets [Highly Emetogenic Chemotherapy (cisplatin dose â‰¥50 mg/m<span class="Sup">2</span>)]
</span></caption>
<col align="left" width="21.050%">
<col align="left" width="27.125%">
<col align="left" width="24.750%">
<col align="left" width="27.075%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">Ondansetron</span></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">Ondansetron</span></td>
<td class="Rrule Toprule" align="left" valign="top"><span class="Bold">Ondansetron</span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold">24 mg once daily</span></td>
<td align="left" valign="top"><span class="Bold">8 mg twice daily</span></td>
<td class="Rrule" align="left" valign="top"><span class="Bold">32 mg once daily</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Adverse Event</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">N=300</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">N=124</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">N=117</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule" align="left" valign="top">33 (11%)
</td>
<td class="Botrule" align="left" valign="top">16 (13%)
</td>
<td class="Botrule Rrule" align="left" valign="top">17 (15%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule" align="left" valign="top">13 (4%)
</td>
<td class="Botrule" align="left" valign="top">9 (7%)
</td>
<td class="Botrule Rrule" align="left" valign="top">3 (3%)
</td>
</tr>
</tbody>
</table>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Adverse Events Reported in â‰¥5% of Adult Patients After Three Days of Therapy With Ondansetron HCl Tablets [Moderately Emetogenic Chemotherapy (primarily cyclophosphamide-based regimens)]
</span></caption>
<col align="left" width="21.325%">
<col align="left" width="25.750%">
<col align="left" width="27.850%">
<col align="left" width="25.075%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">Ondansetron</span></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">Ondansetron</span></td>
<td class="Rrule Toprule" align="left" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold">8 mg twice daily</span></td>
<td align="left" valign="top"><span class="Bold">8 mg three times daily</span></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Adverse Event</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">N=242</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">N=415</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">N=262</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule" align="left" valign="top">58 (24%)
</td>
<td class="Botrule" align="left" valign="top">113 (27%)
</td>
<td class="Botrule Rrule" align="left" valign="top">34 (13%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>
</td>
<td class="Botrule" align="left" valign="top">32 (13%)
</td>
<td class="Botrule" align="left" valign="top">37 (9%)
</td>
<td class="Botrule Rrule" align="left" valign="top">6 (2%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule" align="left" valign="top">22 (9%)
</td>
<td class="Botrule" align="left" valign="top">26 (6%)
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (&lt;1%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule" align="left" valign="top">15 (6%)
</td>
<td class="Botrule" align="left" valign="top">16 (4%)
</td>
<td class="Botrule Rrule" align="left" valign="top">10 (4%)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Central Nervous System:</span> There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving ondansetron.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Italics">Hepatic:</span>  In 723 patients receiving cyclophosphamide-based chemotherapy in US clinical trials, AST and/or ALT values have been reported to exceed twice the upper limit of normal in approximately 1% to 2% of patients receiving ondansetron HCl tablets. The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> did not occur. The role of cancer chemotherapy in these biochemical changes cannot be clearly determined. There have been reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> is unclear.
</p>
<p><span class="Italics">Integumentary: </span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> has occurred in approximately 1% of patients receiving ondansetron.
</p>
<p><span class="Italics">Other: </span> Rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, angina (<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, electrocardiographic alterations, vascular occlusive events, and <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizures</span> have been reported. Except for <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, the relationship to ondansetron was unclear.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Underline">Radiation-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></p>
<p>The adverse events reported in patients receiving ondansetron HCl tablets and concurrent radiotherapy were similar to those reported in patients receiving ondansetron HCl tablets and concurrent chemotherapy. The most frequently reported adverse events were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Adverse Events Reported in â‰¥5% of Adult Patients After Single Dose Therapy With Ondansetron HCl Tablets
</span></caption>
<col align="left" width="29.076%">
<col align="left" width="32.277%">
<col align="left" width="38.646%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> Adverse Events: With the exception of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, rates of these events were not significantly different in the ondansetron and placebo groups.
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">b</span> Patients were receiving multiple concomitant perioperative and postoperative medications.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"><span class="Bold">Ondansetron 16 mg</span></td>
<td class="Rrule Toprule" align="left" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">
<span class="Bold">Adverse Event
</span><span class="Bold"><span class="Sup">a,b</span></span>
</td>
<td class="Botrule" align="left" valign="top"><span class="Bold">N=550</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">N=531</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule" align="left" valign="top">49 (9%)
</td>
<td class="Botrule Rrule" align="left" valign="top">27 (5%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span>
</td>
<td class="Botrule" align="left" valign="top">49 (9%)
</td>
<td class="Botrule Rrule" align="left" valign="top">35 (7%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>
</td>
<td class="Botrule" align="left" valign="top">45 (8%)
</td>
<td class="Botrule Rrule" align="left" valign="top">34 (6%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule" align="left" valign="top">36 (7%)
</td>
<td class="Botrule Rrule" align="left" valign="top">34 (6%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Gynecological disorder
</td>
<td class="Botrule" align="left" valign="top">36 (7%)
</td>
<td class="Botrule Rrule" align="left" valign="top">33 (6%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>/<span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>
</td>
<td class="Botrule" align="left" valign="top">33 (6%)
</td>
<td class="Botrule Rrule" align="left" valign="top">29 (5%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>
</td>
<td class="Botrule" align="left" valign="top">28 (5%)
</td>
<td class="Botrule Rrule" align="left" valign="top">18 (3%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>
</td>
<td class="Botrule" align="left" valign="top">27 (5%)
</td>
<td class="Botrule Rrule" align="left" valign="top">20 (4%)
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of oral formulations of ondansetron. Because these events are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron.
</p>
<p><span class="Italics">Cardiovascular</span>:  Rarely and predominantly with intravenous ondansetron, transient ECG changes including QT interval prolongation have been reported.
</p>
<p><span class="Italics">General</span>: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, sometimes severe (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> reactions, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>) have also been reported. <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">Laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span> have occurred during <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in patients receiving injectable ondansetron.
</p>
<p><span class="Italics">Hepatobiliary</span>: Liver enzyme abnormalities
</p>
<p><span class="Italics">Lower Respiratory</span>: <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span>
</p>
<p><span class="Italics">Neurology</span>: <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">Oculogyric crisis</span>, appearing alone, as well as with other <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>
</p>
<p><span class="Italics">Skin</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span>: Cases of <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">transient blindness</span>, predominantly during intravenous administration, have been reported. These cases of <span class="product-label-link" type="condition" conceptid="372627" conceptname="Transient visual loss">transient blindness</span> were reported to resolve within a few minutes up to 48 hours.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s38"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Apomorphine
</h2>
<p class="First">Based on reports of profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> when apomorphine was administered with ondansetron, the concomitant use of apomorphine with ondansetron is contraindicated [<span class="Italics">see Contraindications (<a href="#s23">4</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Phenytoin, Carbamazepine, Rifampicin
</h2>
<p class="First">In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.<span class="Sup">1,3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Serotonergic Drugs
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> (including altered mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, and neuromuscular symptoms) has been described following the concomitant use of 5-HT 3 receptor antagoinists and other serotonergic drugs, including selective serotonin reuptake inhibitor (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) <span class="Italics">[see Warnings and Precautions (<a href="#s27">5.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Tramadol
</h2>
<p class="First">Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small studies indicate that concomitant use of ondansetron may result in reduced analgesic activity of tramadol. Patients in the studies self-administered tramadol more frequently, leading to an increased cumulative dose in patient controlled administration (PCA) of tramadol.<span class="Sup">4,5</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Chemotherapy
</h2>
<p class="First">In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.
</p>
<p>In a crossover study in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Temazepam
</h2>
<p class="First">The co-administration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Antacids
</h2>
<p class="First">Bioavailability of ondansetron is unaffected by antacids
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Alfentanil and Atracurium
</h2>
<p class="First">Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> produced by atracurium. Interactions with general or local anesthetics have not been studied.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s47"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s48"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category B. Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg/day, respectively  (approximately  8 and 30 times the  human dose of 16 mg/day, based on body surface area), and have revealed no evidence of impaired fertility or harm to the fetus due to ondansetron. There are, however, no adequate and well- controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ZUPLENZ (ondansetron) oral soluble film should be used during pregnancy only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s49"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Ondansetron is excreted in the milk of rats. It is not known whether ondansetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ZUPLENZ oral soluble film is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s50"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Little information is available about dosage in pediatric patients less than 4 years of age. For dosage recommendations in the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with moderately emetogenic cancer chemotherapy for patients 4 years of age and older <span class="Italics">[see Dosage and Administration (<a href="#s11">2.2</a>)]</span>. The safety and effectiveness in pediatric patients have not been established for the following indications: prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic cancer chemotherapy, prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with radiotherapy, and prevention of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s51"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Of the total number of subjects enrolled in cancer chemotherapy-induced and <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in US- and foreign- controlled clinical trials, for which there were subgroup analyses, 938 were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dosage adjustment is not needed in patients over the age of 65 [<span class="Italics">see Clinical Pharmacology (<a href="#s60">12.3</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">The dosage recommendation is the same as for the general population. There is no experience beyond first-day administration of ondansetron.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 or greater)<span class="Sup">2</span>, clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life [<span class="Italics">see Clinical Pharmacology (<a href="#s60">12.3</a>)</span>]. In such patients, a total daily dose of 8 mg should not be exceeded.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s54"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<p class="First">Animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s55"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">There is no specific antidote for ondansetron <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Patients should be managed with appropriate supportive therapy. Individual intravenous doses as large as 150 mg and total daily intravenous doses as large as 252 mg have been inadvertently administered without significant adverse events. These doses are more than 10 times the recommended daily dose.
</p>
<p>In addition to the adverse events listed above, the following events have been described in the setting of ondansetron <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>: â€œSudden blindnessâ€? (<span class="product-label-link" type="condition" conceptid="4290687" conceptname="Amaurosis">amaurosis</span>) of 2 to 3 minutes' duration plus severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> occurred in 1 patient that was administered 72 mg of ondansetron intravenously as a single dose. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (and faintness) occurred in a patient that took 48 mg of ondansetron HCl tablets. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> was observed. In all instances, the events resolved completely.
</p>
<p>Pediatric cases consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported after inadvertent oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of ondansetron (exceeding estimated ingestion of 5 mg/kg) in young children. Reported symptoms included <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, myoclonic movements, horizontal <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Patients required supportive care, including intubation in some cases, with complete recovery without sequelae within 1 to 2 days.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s56"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">ZUPLENZ (ondansetron) oral soluble film is a white opaque orally dissolving film designed to be applied on top of the tongue where it will dissolve in 4 to 20 seconds and then is swallowed with saliva.
</p>
<p>ZUPLENZ does not require water to aid dissolution or swallowing.
</p>
<p>The active ingredient in ZUPLENZ is ondansetron base, the racemic form of ondansetron, and a selective blocking agent of the serotonin 5-HT<span class="Sub">3</span> receptor type. Chemically it is (Â±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H- carbazol-4-one.
</p>
<p><a name="f01"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0000-01.jpg"><p class="MultiMediaCaptionNotCentered">Figure 1: Structural formula of ondansetron
</p></p>
<p>The empirical formula is C<span class="Sub">18</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O representing a molecular weight of 293.3. Each 4-mg ZUPLENZ oral soluble film for oral administration contains 4 mg ondansetron base.  Each 8-mg ZUPLENZ oral soluble film for oral administration contains 8 mg ondansetron base.  Each ZUPLENZ oral soluble film also contains the inactive ingredients butylated hydroxytoluene, calcium carbonate, colloidal silicon dioxide, erythritol, hypromellose, monoammonium glycyrrhizinate, peppermint flavor, polyethylene oxide, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, sucralose, titanium dioxide and xanthan gum.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s57"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s58"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Ondansetron is a selective 5-HT<span class="Sub">3</span> receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT<span class="Sub">3</span> type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether ondansetron' s antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.  In humans, urinary 5-HIAA (5-hydroxyindoleacetic acid) excretion increases after cisplatin administration in parallel with the onset of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.  The released serotonin may stimulate the vagal afferents through the 5- HT<span class="Sub">3</span> receptors and initiate the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> reflex. In animals, the emetic response to cisplatin can be prevented by pretreatment with an inhibitor of serotonin synthesis, bilateral abdominal vagotomy and greater splanchnic nerve section, or pretreatment with a serotonin 5-HT<span class="Sub">3</span> receptor antagonist.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s59"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers. Ondansetron has no effect on plasma prolactin concentrations.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s60"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Ondansetron is well absorbed from the gastrointestinal tract and undergoes some first-pass metabolism. After a single dose of ZUPLENZ (ondansetron) oral soluble film 8 mg under fasting conditions (n=46), the peak plasma concentrations were achieved in 1.3 hours and the mean elimination half-life was 4.6 hours in healthy subjects.  The mean (Â±S.D.) C<span class="Sub">max</span> and AUC were 37.28 (Â±14.9) ng/mL and 225 (Â±88.1) ngÂ·h/mL, respectively. In the same study, mean ondansetron C<span class="Sub">max</span> and AUC following administration of 8 mg ZUPLENZ oral soluble film were comparable to those after 8 mg ondansetron ODT (orally disintegrating tablet). The systemic exposure after administration of ZUPLENZ oral soluble film 8 mg with or without water was found to be comparable.
</p>
<p>In a study using ondansetron tablets, ondansetron systemic exposure did not increase proportionately to dose. AUC from a 16 mg tablet was 24% greater than predicted from an 8 mg tablet dose. This may reflect some reduction of first-pass metabolism at higher oral doses.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Underline">Food Effect</span></p>
<p>When administered with a high fat meal, 8 mg ZUPLENZ (ondansetron) oral soluble film's mean time to peak plasma concentration (t<span class="Sub">max</span>) was delayed by approximately 1 hour and its AUC remained similar compared to that of under fasted stated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL. Circulating drug also distributes into erythrocytes.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-12.3.4"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Excretion</span></p>
<p>Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine. <span class="Underline">The metabolites are observed in the urine.</span> The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation.
</p>
<p>In vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role.
</p>
<p>Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-12.3.5"></a><p></p>
<p class="First">Drug Interactions
</p>
<p>Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver.
</p>
<p>Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of available data, no dosage adjustment is recommended for patients on these drugs. Based on the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by others and may result in little change in overall rates of ondansetron elimination.
</p>
<p>On the basis of available limited data, no dosage adjustment for ondansetron is recommended for patients on inhibitors of a single CYP enzyme.
</p>
<p>Ondansetron elimination may be affected by cytochrome P-450 inducers. In a pharmacokinetic study of 16 epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin, reduction in AUC, C<span class="Sub">max</span>, and TÂ½ of ondansetron was observed<span class="Sup">1</span>; this resulted in a significant increase in clearance. However, on the basis of available data, no dosage adjustment for ondansetron is recommended.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-12.3.6"></a><p></p>
<p class="First"><span class="Bold Underline">Specific Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-12.3.7"></a><p></p>
<p class="First"><span class="Underline">Gender</span></p>
<p>Gender differences were shown in the disposition of ondansetron given as a single dose. The extent and rate of ondansetron' s absorption is greater in women than men. It is not known whether these gender-related differences are clinically important.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Mean Pharmacokinetic Parameters by Gender in Healthy Volunteers After A Single 8 mg ZUPLENZ Oral Soluble Film Dose
</span></caption>
<col align="left" width="14.286%">
<col align="left" width="14.286%">
<col align="left" width="14.286%">
<col align="left" width="14.286%">
<col align="left" width="14.286%">
<col align="left" width="14.286%">
<col align="left" width="14.286%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Gender</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Mean Weight (kg)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">n</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold"><span class="Sup">C</span></span><span class="Bold">max
</span><span class="Bold">(ng/mL)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold"><span class="Sup">T</span></span><span class="Bold">max
</span><span class="Bold">(h)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold"><span class="Sup">T</span></span><span class="Bold">1/2</span><br><span class="Bold">(h)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">AUC</span><br><span class="Bold">(hÂ·ng/mL)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">M
</td>
<td class="Rrule" align="center" valign="top">62
</td>
<td class="Rrule" align="center" valign="top">39
</td>
<td class="Rrule" align="center" valign="top">35.2
</td>
<td class="Rrule" align="center" valign="top">1.67
</td>
<td class="Rrule" align="center" valign="top">4.54
</td>
<td class="Rrule" align="center" valign="top">207
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">F
</td>
<td class="Botrule Rrule" align="center" valign="top">56.7
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">49.1
</td>
<td class="Botrule Rrule" align="center" valign="top">1.7
</td>
<td class="Botrule Rrule" align="center" valign="top">5.39
</td>
<td class="Botrule Rrule" align="center" valign="top">323
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-12.3.8"></a><p></p>
<p class="First"><span class="Underline">Elderly</span></p>
<p>A reduction in clearance and increase in elimination half-life are seen in patients over 75 years of age. In clinical trials with cancer patients, safety and efficacy was similar in patients over 65 years of age and those under 65 years of age; there was an insufficient number of patients over 75 years of age to permit conclusions in that age-group. No dosage adjustment is recommended in the elderly.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-12.3.9"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>In patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in healthy subjects. In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 10 or greater)<span class="Sup">2</span>, clearance is reduced 2-fold to 3-fold and apparent volume of distribution is increased with a resultant increase in half-life to 20 hours. In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, a total daily dose of 8 mg should not be exceeded.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-12.3.10"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Due to the very small contribution (5%) of renal clearance to the overall clearance, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was not expected to significantly influence the total clearance of ondansetron. However, ondansetron oral mean plasma clearance was reduced by about 50% in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min). This reduction in clearance is variable and was not consistent with  an increase in half-life. No reduction in dose or dosing frequency in these patients is warranted.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s71"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s72"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Carcinogenic effects were not seen in 2-year studies in rats and mice with oral ondansetron doses up to 10 mg/kg/day and 30 mg/kg/day, respectively (approximately 5 and 8 times the human dose of 16 mg/day, based on body surface area). Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of ondansetron up to 15 mg/kg/day (approximately 8 times the human dose of 16 mg/day, based on body surface area) did not affect fertility or general reproductive performance of male and female rats.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s73"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">The clinical efficacy of ondansetron, the active ingredient of ZUPLENZ, was assessed in clinical trials as described below.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-14.1.1"></a><p></p>
<p class="First"><span class="Underline">Highly Emetogenic Chemotherapy</span></p>
<p>In 2 randomized, double-blind, monotherapy trials, a single 24 mg ondansetron HCl tablet was superior to a relevant historical placebo control in the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic cancer chemotherapy, including cisplatin â‰¥50 mg/m<span class="Sup">2</span>. Steroid administration was excluded from these clinical trials.  More than 90% of patients receiving a cisplatin dose â‰¥50 mg/m<span class="Sup">2</span> in the historical placebo comparator experienced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in the absence of antiemetic therapy.
</p>
<p>The first trial compared oral doses of ondansetron 24 mg once a day, 8 mg twice a day, and 32 mg once a day in 357 adult cancer patients receiving chemotherapy regimens containing cisplatin â‰¥50 mg/m<span class="Sup">2</span>.  A total of 66% of patients in the ondansetron 24 mg once- a-day group, 55% in the ondansetron 8 mg twice-a-day group, and 55% in the ondansetron 32 mg once-a-day group completed the 24- hour study period with 0 emetic episodes and no rescue antiemetic medications, the primary endpoint of efficacy. Each of the 3 treatment groups was shown to be statistically significantly superior to a historical placebo control.
</p>
<p>In the same trial, 56% of patients receiving oral ondansetron 24 mg once a day experienced no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> during the 24-hour study period, compared with 36% of patients in the oral ondansetron 8 mg twice-a-day group (p = 0.001) and 50% in the oral ondansetron 32 mg once-a-day group.
</p>
<p>In a second trial, efficacy of the oral ondansetron 24 mg once-a-day regimen in the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with highly emetogenic cancer chemotherapy, including cisplatin â‰¥50 mg/m<span class="Sup">2</span>, was confirmed.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-14.1.2"></a><p></p>
<p class="First"><span class="Underline">Moderately Emetogenic Chemotherapy</span></p>
<p>In 1 double-blind US study in 67 patients, ondansetron HCl tablets 8 mg administered twice a day were significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> induced by cyclophosphamide-based chemotherapy containing doxorubicin. Treatment response is based on the total number of emetic episodes over the 3-day study period. The results of this study are summarized in <a href="#t5">Table 5</a>.
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5:Emetic Episodes: Treatment Response After Ondansetron HCl Tablets 8 mg Twice A Day
</span></caption>
<col align="left" width="26.850%">
<col align="left" width="21.575%">
<col align="left" width="20.475%">
<col align="left" width="31.100%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">a</span> The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. An 8-mg ondansetron HCl tablet was administered twice a day for 2 days after completion of chemotherapy.
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">b</span> Median undefined since at least 50% of the patients were withdrawn or had more than 2 emetic episodes.
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">c</span> Median undefined since at least 50% of patients did not have any emetic episodes.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"></td>
<td class="Rrule Toprule" align="left" colspan="3" valign="top"><span class="Bold">Ondansetron</span></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"></td>
<td class="Rrule" align="left" colspan="3" valign="top"><span class="Bold">Tablet</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">
<span class="Bold">8 mg twice daily
</span><span class="Bold"><span class="Sup">a</span></span>
</td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">p Value</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Number of patients</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">33</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">34</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top">Treatment response
</td></tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">0 emetic episodes
</td>
<td class="Botrule" align="left" valign="top">20 (61%)
</td>
<td class="Botrule" align="left" valign="top">2 (6%)
</td>
<td class="Botrule Rrule" align="left" valign="top">&lt;0.001
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">1-2 emetic episodes
</td>
<td class="Botrule" align="left" valign="top">6 (18%)
</td>
<td class="Botrule" align="left" valign="top">8 (24%)
</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">&gt;2 emetic episodes/ withdrawn
</td>
<td align="left" valign="top">7 (21%)
</td>
<td align="left" valign="top">24 (71%)
</td>
<td class="Rrule" align="left" valign="top">&lt;0.001
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Median number of emetic episodes
</td>
<td align="left" valign="top">0.0
</td>
<td align="left" valign="top">Undefined<span class="Sup">b</span>
</td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">Median time to first emetic episode (h)
</td>
<td class="Botrule" align="left" valign="top">Undefined<span class="Sup">c</span>
</td>
<td class="Botrule" align="left" valign="top">6.5
</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>In 1 double-blind US study in 336 patients, ondansetron HCl tablets 8 mg administered twice a day were as effective as ondansetron HCl tablets 8 mg administered 3 times a day in preventing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> induced by cyclophosphamide-based chemotherapy containing either methotrexate or doxorubicin.
</p>
<p>Treatment response is based on the total number of emetic episodes over the 3-day study period. The results of this study are summarized in <a href="#t6">Table 6</a>.
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6:Emetic Episodes: Treatment Response After Ondansetron HCl Tablets 8 mg Twice A Day and Three Times A Day
</span></caption>
<col align="left" width="39.967%">
<col align="left" width="27.000%">
<col align="left" width="33.033%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. An 8-mg ondansetron HCl tablet was administered twice a day for 2 days after completion of chemotherapy.
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">b</span> The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. An 8-mg
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">ondansetron HCl tablet was administered three times daily for 2 days after completion of chemotherapy.
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">c</span> Median undefined since at least 50% of patients did not have any emetic episodes.
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">d</span> Visual analog scale assessment: 0=no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 100=<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> as bad as it can be.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Ondansetron 8 mg twice daily
</span><span class="Bold"><span class="Sup">a</span></span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Ondansetron 8 mg three times daily</span><span class="Bold"><span class="Sup">b</span></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Number of patients</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">165</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">171</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top">Treatment response
</td></tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">0 emetic episodes
</td>
<td class="Botrule" align="left" valign="top">101 (61%)
</td>
<td class="Botrule Rrule" align="left" valign="top">99 (58%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">1-2 emetic episodes
</td>
<td class="Botrule" align="left" valign="top">16 (10%)
</td>
<td class="Botrule Rrule" align="left" valign="top">17 (10%)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">&gt;2 emetic episodes/withdrawn
</td>
<td class="Botrule" align="left" valign="top">48 (29%)
</td>
<td class="Botrule Rrule" align="left" valign="top">55 (32%)
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Median number of emetic episodes
</td>
<td align="left" valign="top">0.0
</td>
<td class="Rrule" align="left" valign="top">0.0
</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Median time to first emetic episode (h)
</td>
<td align="left" valign="top">Undefined<span class="Sup">c</span>
</td>
<td class="Rrule" align="left" valign="top">Undefined<span class="Sup">c</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">Median <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> scores (0-100)<span class="Sup">d</span>
</td>
<td class="Botrule" align="left" valign="top">6
</td>
<td class="Botrule Rrule" align="left" valign="top">6
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-14.1.3"></a><p></p>
<p class="First"><span class="Underline">Retreatment</span></p>
<p>In uncontrolled trials, 148 patients receiving cyclophosphamide-based chemotherapy were re-treated with ondansetron HCl tablets 8 mg three times daily during subsequent chemotherapy for a total of 396 re-treatment courses. No emetic episodes occurred in 314 (79%) of the re-treatment courses, and only 1 to 2 emetic episodes occurred in 43 (11%) of the re-treatment courses.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-14.1.4"></a><p></p>
<p class="First"><span class="Underline">Pediatrics</span></p>
<p>Three open-label, uncontrolled, foreign trials have been performed with 182 pediatric patients 4 to 18 years old with cancer who were given a variety of cisplatin or non-cisplatin regimens. In these foreign trials, the initial dose of ondansetron HCl injection ranged from 0.04 mg/kg to 0.87 mg/kg for a total dose of 2.16 mg to 12 mg. This was followed by the administration of ondansetron HCl tablets ranging from 4 mg to 24 mg daily for 3 days. In these studies, 58% of the 170 evaluable patients had a complete response (no emetic episodes) on day 1. Two studies showed the response rates for patients less than 12 years of age who received ondansetron HCl tablets 4 mg three times daily to be similar to those in patients 12 to 18 years of age who received ondansetron HCl tablets 8 mg three times daily. Thus, prevention of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> in these pediatric patients was essentially the same as for patients older than 18 years of age. Overall, ondansetron HCl tablets were tolerated in these pediatric patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-14.2"></a><p></p>
<h2>14.2 Radiation-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-14.2.1"></a><p></p>
<p class="First"><span class="Underline">Total Body Irradiation</span></p>
<p>In a randomized, double-blind study in 20 patients, ondansetron HCl tablets (8 mg given 1.5 hours before each fraction of  radiotherapy for 4 days) were significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> induced by total body irradiation. Total body irradiation consisted of 11 fractions (120 cGy per fraction) over 4 days for a total of 1,320 cGy. Patients received 3 fractions for 3 days, then 2 fractions on day 4.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-14.2.2"></a><p></p>
<p class="First"><span class="Underline">Single High-Dose Fraction Radiotherapy</span></p>
<p>Ondansetron was significantly more effective than metoclopramide with respect to complete control of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (0 emetic episodes) in a double-blind trial in 105 patients receiving single high-dose radiotherapy (800 to 1,000 cGy) over an anterior or posterior field size of â‰¥80 cm<span class="Sup">2</span> to the abdomen.  Patients received the first dose of ondansetron HCl tablets (8 mg) or metoclopramide (10 mg) 1 to 2 hours before radiotherapy.  If radiotherapy was given in the morning, 2 additional doses of study treatment were given (1 tablet late afternoon and 1 tablet before bedtime).  If radiotherapy was given in the afternoon, patients took only 1 further tablet that day before bedtime.  Patients continued the oral medication on a three times daily basis for 3 days.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-14.2.3"></a><p></p>
<p class="First"><span class="Underline">Daily Fractionated Radiotherapy</span></p>
<p>Ondansetron was significantly more effective than prochlorperazine with respect to complete control of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (0 emetic episodes) in a double-blind trial in 135 patients receiving a 1- to 4-week course of fractionated radiotherapy (180 cGy doses) over a field size of &gt;100 cm<span class="Sup">2</span> to the abdomen. Patients received the first dose of ondansetron HCl tablets (8 mg) or prochlorperazine (10 mg) 1 to 2 hours before the patient received the first daily radiotherapy fraction, with 2 subsequent doses on a three times a day basis. Patients continued the oral medication on a three times daily basis on each day of radiotherapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-14.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">Postoperative Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</h2>
<p class="First">Surgical patients who received ondansetron 1 hour before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil, sufentanil, morphine, or fentanyl; nitrous oxide; <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>: succinylcholine/curare or gallamine and/or vecuronium, pancuronium, or atracurium; and supplemental isoflurane or enflurane) were evaluated in 2 double-blind studies (1 US study, 1 foreign) involving 865 patients. Ondansetron HCl tablets (16 mg) were significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
<p>The study populations in all trials thus far consisted of women undergoing inpatient surgical procedures. No studies have been performed in males. No controlled clinical study comparing ondansetron HCl tablets to ondansetron injection has been performed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s84"></a><a name="section-15"></a><p></p>
<h1>15 REFERENCES
</h1>
<ol class="Arabic">
<li>Britto MR, Hussey EK, Mydlow P, et al. Effect of enzyme inducers on ondansetron (OND) metabolism in humans. Clin Pharmacol Ther. 1997;61:228.
</li>
<li>Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for <span class="product-label-link" type="condition" conceptid="28779" conceptname="Bleeding esophageal varices">bleeding oesophageal varices</span>. Brit J Surg. 1973;60:646-649.
</li>
<li>Villikka K, Kivisto KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999;65:377-381.
</li>
<li>De Witte JL, Schoenmaekers B, Sessler DI, et al. Anesth Analg. 2001;92:1319-1321.
</li>
<li>Arcioni R, della Rocca M, RomanÃ² R, et al. Anesth Analg. 2002;94:1553-1557.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s85"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">ZUPLENZ (ondansetron) oral soluble film 4 mg and ZUPLENZ (ondansetron) oral soluble film 8 mg, are supplied as thin rectangular white opaque films in individual foil-foil sealed child resistant pouches. Individual films are identified by â€œ4 mgâ€? or â€œ8 mgâ€?, according to the respective strengths, which is printed using pharmaceutical grade edible ink.
</p>
<p>Individual pouches of ZUPLENZ 4 mg oral soluble film are packaged in boxes of 10 (NDC 57881-444-10) and packaged in boxes of 1 (NDC 57881-444-01).  Individual pouches of ZUPLENZ 8 mg oral soluble film are packaged in boxes of 10 (NDC 57881-448-10) and packaged in boxes of 1 (NDC 57881-448-01).
</p>
<p>Store at controlled room temperature 20Â° to 25Â°C (68Â° to 77Â°F). Store pouches in cartons. Keep product in pouch until ready to use.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s86"></a><a name="section-17"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">See <a href="#s87">FDA-Approved Patient Labeling</a></p>
<p>Advise patients to carefully read the â€œ<a href="#s87">Patient Information</a>â€? and â€œ<a href="#s88">Instructions for Use</a>â€? accompanying each package of ZUPLENZ (ondansetron) oral soluble film.
</p>
<p>Inform patients that ZUPLENZ may cause serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> such as QT prolongation. Instruct patients to tell their healthcare provider right away if they perceive a change in their heart rate, if they feel lightheaded, or if they have a syncopal episode.
</p>
<p>Inform patients that the chances of developing severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> such as QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> are higher in the following people:
</p>
<ul class="Circle">
<li>Patients with a personal or family history of abnormal heart rhythms, such as congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>;
</li>
<li>Patients who take medications, such as diuretics, which may cause electrolyte abnormalities
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesaemia</span>
</li>
</ul>
<dl class="Circle">
<dt>Â 
</dt>
<dd>ZUPLENZ should be avoided in these patients, since they may be more at risk for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> such as QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>.
</dd>
</dl>
<ul class="Circle"><li>Advise patients of the possibility of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with concomitant use of Zuplenz and another serotonergic agent such as medications to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, neuromuscular symptoms with or without <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>.
</li></ul>
<p>Inform patients that ZUPLENZ film may cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. The patient should report the use of all medications, especially apomorphine or any drug of the 5HT3 antagonist class, to their health care provider. Concomitant use of apomorphine and ondansetron may cause a significant <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>.
</p>
<p>Inform patients that ZUPLENZ may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, some as severe as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.  The patient should report any <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to this and other 5-HT<span class="Sub">3</span> receptor antagonists to their health care provider.
</p>
<p>Instruct patients on how to use ZUPLENZ films:
</p>
<p>The patient should keep the film in the pouch until ready to use and not to chew or swallow the film. With dry hands, the patient should fold the pouch along the dotted line to expose the tear notch. While still folded, the patient should tear the pouch carefully along the edge and remove the ZUPLENZ oral soluble film from the pouch. The patient should immediately place the film on top of the tongue where it dissolves in 4 to 20 seconds, then swallow with saliva. Once the film dissolves, the patient may swallow liquid but it is not required. The patient should wash his hands after taking ZUPLENZ.
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s87"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Patient Information <br>ZUPLENZ</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">(ZOO-plenz) <br>(ondansetron)</span></p>
<p><span class="Bold">Oral Soluble Film</span></p>
<p><span class="Bold">What is ZUPLENZ</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">?</span></p>
<p>ZUPLENZ is a prescription medicine that is used in adults to prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>:
</p>
<ul class="Disc">
<li>that happens with certain cancer chemotherapy medicines, radiation therapy to your stomach-area (abdomen), or radiation therapy to your entire body.
</li>
<li>that may happen after surgery
</li>
</ul>
<p>In children 4 years of age and older, ZUPLENZ is only used to prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that happens with certain cancer chemotherapy medicines.
</p>
<p>It is not known if ZUPLENZ is safe and works in children to prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> with radiation therapy, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that may happen after surgery in children.
</p>
<p><span class="Bold">Who should not take ZUPLENZ? Do not take ZUPLENZ if you:</span></p>
<ul class="Disc">
<li>take apomorphine hydrochloride (Apokyn)
</li>
<li>have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ZUPLENZ or are allergic to any of its ingredients. See the end of this leaflet for a complete list of ingredients in ZUPLENZ.
</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking ZUPLENZ? Before you take ZUPLENZ, tell you doctor if you:</span></p>
<ul class="Disc">
<li>have any heart problems, including a condition called â€œcongenital <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">long QT</span> syndromeâ€?
</li>
<li>take a medicine that causes heart problems (QT prolongation)
</li>
<li>have low blood levels of potassium or magnesium
</li>
<li>have liver problems
</li>
<li>have any other medical conditions
</li>
<li>are pregnant or plan to become pregnant. It is not known if ZUPLENZ will harm your unborn baby.
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if ZUPLENZ passes into your breast milk.
</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how ZUPLENZ works, and ZUPLENZ may affect how other medicines work. Taking ZUPLENZ with certain other medicines may cause serious side effects. Especially tell your doctor if you take:
</p>
<ul class="Disc">
<li>apomorphine hydrochloride (Apokyn)
</li>
<li>tramadol hydrochloride (Ultram, Ultram ER, Ryzolt, ConZip, Rybix ODT)
</li>
<li>any other medicine for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
</li>
</ul>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
</p>
<p><span class="Bold">How should I take ZUPLENZ?</span></p>
<ul class="Disc">
<li>Take ZUPLENZ exactly as your doctor tells you to take it.
</li>
<li>If you take too much ZUPLENZ, call your doctor or go to the nearest hospital emergency room right away.
</li>
<li>An adult should help a young child use ZUPLENZ.
</li>
</ul>
<p>Read the <a href="#s88">Instructions for Use</a> at the end of this Patient Information for information about the right way to take ZUPLENZ.
</p>
<p><span class="Bold">What should I avoid while taking ZUPLENZ?</span></p>
<p>ZUPLENZ may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Do not drive, operate machinery, or do other dangerous activities until you know how ZUPLENZ affects you.
</p>
<p><span class="Bold">What are the possible side effects of ZUPLENZ?</span></p>
<p><span class="Bold">ZUPLENZ may cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span>. Stop taking ZUPLENZ and get medical help right away if you have any of these signs or symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ZUPLENZ:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>
</li>
<li>trouble breathing
</li>
<li><span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your mouth, face, lips, or tongue
</li>
</ul>
</li>
<li>
<span class="Bold">heart rhythm changes.</span> ZUPLENZ can cause a change in the electrical activity in your heart called QT prolongation, which can cause irregular heartbeats.
</li>
</ul>
<p>The most common side effects of ZUPLENZ include:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> and body <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
</li>
</ul>
<p>These are not all the possible side effects of ZUPLENZ. For more information, ask your doctor or pharmacist.
</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">How should I store ZUPLENZ?</span></p>
<ul class="Disc">
<li>Store ZUPLENZ at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).
</li>
<li>Keep ZUPLENZ in the foil pouch until ready to use. Keep foil pouches in the carton.
</li>
<li>Use ZUPLENZ right after you take it out of the pouch.
</li>
</ul>
<p><span class="Bold">Keep ZUPLENZ and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of ZUPLENZ</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use ZUPLENZ for a condition for which it was not prescribed. Do not give ZUPLENZ to other people, even if they have the same symptoms that you have. It may harm them.
</p>
<p>You can ask your doctor or pharmacist for information about ZUPLENZ that is written for health professionals.
</p>
<p>For more information, go to <span class="Underline">www.ZUPLENZ.com</span> or call 1 855 636 5710.
</p>
<p><span class="Bold">What are the ingredients in ZUPLENZ?</span></p>
<p><span class="Bold">Active ingredient:</span> ondansetron
</p>
<p><span class="Bold">Inactive ingredients:</span> butylated hydroxytoluene, calcium carbonate, colloidal silicon dioxide, erythritol, hypromellose, monoammonium glycyrrhizinate, peppermint flavor, polyethylene oxide, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, sucralose, titanium dioxide and xanthan gum.
</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.
</p>
<p>Manufactured by:<br>Monosol Rx, LLC<br>Warren, NJ 07059
</p>
<p>Manufactured for:<br>Galena Biopharma, Inc.<br>Portland, OR 97239
</p>
<p>Distributed by:<br>Galena Biopharma, Inc. Portland, OR 97239
</p>
<p>Revised: September 2014
</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="s88"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Instructions for Use <br>ZUPLENZ</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">(ZOO-plenz) <br>(ondansetron)<br>Oral Soluble Film</span></p>
<p><span class="Bold">Step 1.</span> Keep the ZUPLENZ film in the foil pouch until ready to use. Use ZUPLENZ film right away after you take it out of the pouch.
</p>
<p><span class="Bold">Step 2.</span> Make sure your hands are dry.
</p>
<p><span class="Bold">Step 3.</span> Fold the pouch along the dotted line to expose the tear notch. See <a href="#figa">Figure A</a>.
</p>
<p><a name="figa"></a><a name="f02"></a><img alt="Figure A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0001-02.jpg">Â  Â  Â  Â Figure A
</p>
<p><span class="Bold">Step 4.</span> While still folded, tear the pouch carefully along the edge. See <a href="#figb">Figure B</a>.
</p>
<p><a name="figb"></a><a name="f03"></a><img alt="Figure B
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0001-03.jpg">Â  Â  Â  Â Figure B
</p>
<p><span class="Bold">Step 5.</span> Take the ZUPLENZ film out of the pouch. See <a href="#figc">Figure C</a>.
</p>
<p><a name="figc"></a><a name="f04"></a><img alt="Figure C
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0001-04.jpg">Â  Â  Â  Â Figure C
</p>
<p><span class="Bold">Step 6.</span> Put the ZUPLENZ film on top of your tongue. It will dissolve in 4 to 20 seconds. See <a href="#figd">Figure D</a>.
</p>
<p><a name="figd"></a><a name="f05"></a><img alt="Figure D
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0001-05.jpg">Â  Â  Â  Â Figure D
</p>
<p><span class="Bold">Step 7.</span> Do not chew or swallow the film whole.
</p>
<p><span class="Bold">Step 8.</span> Swallow after the ZUPLENZ film dissolves. You may swallow the dissolved film with or without liquid.
</p>
<p><span class="Bold">Step 9.</span> Wash your hands after taking ZUPLENZ.
</p>
<p><span class="Bold">How should I store ZUPLENZ?</span></p>
<ul class="Disc">
<li>Store ZUPLENZ at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).
</li>
<li>Keep ZUPLENZ in the foil pouch until ready to use. Keep foil pouches in the carton.
</li>
<li>Use ZUPLENZ right after you take it out of the pouch.
</li>
</ul>
<p><span class="Bold">Keep ZUPLENZ and all medicines out of the reach of children.</span></p>
<p>This â€œInstructions for Useâ€? has been approved by the U.S. Food and Drug Administration.
</p>
<p>Manufactured by:<br>Monosol Rx, LLC <br>Warren, NJ 07059
</p>
<p>Manufactured for:<br>Galena Biopharma,  Inc. Portland, OR 97239
</p>
<p>Distributed by:<br>Galena Biopharma, Inc. <br>Portland, OR 97239
</p>
<p>Revised: September 2014
</p>
<p><span class="Bold">Â©</span>2014 Galena Biopharma, Inc.
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s89"></a><a name="section-20"></a><p></p>
<p class="First"><br><br><span class="Bold">â€”â€”â€”PRINCIPAL DISPLAY PANEL - 4 mgâ€”â€”â€”
</span><br><br>NDC 57881-444-10<br><br><span class="Bold">Zuplenz<span class="Sup">Â®</span></span><br>(ondansetron) oral soluble film<br><br><span class="Bold">4 mg
</span><br><br>Rx only<br><br>10 Films
</p>
<div class="Figure">
<a name="f06"></a><img alt="Principal Display Panel - 4 mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0001-06.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s91"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Box Label</span></p>
<p><span class="Bold">TO OPEN:</span> Fold along dotted line and<br>tear down at slit along the arrow.
</p>
<p><span class="Bold">PHYSICIAN SAMPLE</span></p>
<p><span class="Bold">NOT FOR SALE</span></p>
<p><span class="Bold">NDC 57881-444-01</span></p>
<p><span class="Bold Italics">Zuplenz</span><span class="Bold Italics"><span class="Sup">Â®</span></span><span class="Italics"><br>(ondansetron) oral soluble film</span></p>
<p><span class="Bold">4 mg</span></p>
<p>Rx only
</p>
<p><span class="Bold">1 Film</span></p>
<div class="Figure">
<a name="f07"></a><img alt="Principal Display Panel - Box Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0002-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s90"></a><a name="section-22"></a><p></p>
<p class="First"><br><br><span class="Bold">â€”â€”â€”PRINCIPAL DISPLAY PANEL - 8 mgâ€”â€”â€”
</span><br><br>NDC 57881-448-10<br><br><span class="Bold">Zuplenz<span class="Sup">Â®</span></span><br>(ondansetron) oral soluble film<br><br><span class="Bold">8Â mg
</span><br><br>Rx only<br><br>10 Films
</p>
<div class="Figure">
<a name="f08"></a><img alt="Principal Display Panel - 8 mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0002-08.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s92"></a><a name="section-23"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Box Label</span></p>
<p><span class="Bold">TO OPEN:</span> Fold along dotted line and<br>tear down at slit along the arrow.
</p>
<p><span class="Bold">PHYSICIAN SAMPLE</span></p>
<p><span class="Bold">NOT FOR SALE</span></p>
<p><span class="Bold">NDC 57881-448-01</span></p>
<p><span class="Bold Italics">Zuplenz</span><span class="Bold Italics"><span class="Sup">Â®</span></span><span class="Italics"><br>(ondansetron) oral soluble film</span></p>
<p><span class="Bold">8 mg</span></p>
<p>Rx only
</p>
<p><span class="Bold">1 Film</span></p>
<div class="Figure">
<a name="f09"></a><img alt="Principal Display Panel - Box Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed036bdb-b832-440f-82c7-ade2956b73ee&amp;name=zup00-0002-09.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZUPLENZÂ 		
					</strong><br><span class="contentTableReg">ondansetron film, soluble</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-444</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ondansetron</strong> (ondansetron) </td>
<td class="formItem">ondansetron</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ERYTHRITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>AMMONIUM GLYCYRRHIZATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCRALOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-444-10</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:57881-444-01</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022524</td>
<td class="formItem">10/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZUPLENZÂ 		
					</strong><br><span class="contentTableReg">ondansetron film, soluble</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-448</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ondansetron</strong> (ondansetron) </td>
<td class="formItem">ondansetron</td>
<td class="formItem">8Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CARBONATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ERYTHRITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>AMMONIUM GLYCYRRHIZATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCRALOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-448-10</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:57881-448-01</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022524</td>
<td class="formItem">10/08/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Galena Biopharma, Inc.
							(044320456)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Monosol Rx, LLC</td>
<td class="formItem"></td>
<td class="formItem">785935235</td>
<td class="formItem">MANUFACTURE(57881-444, 57881-448)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0a47e753-562e-46c4-8f08-604cceb517ad</div>
<div>Set id: ed036bdb-b832-440f-82c7-ade2956b73ee</div>
<div>Version: 3</div>
<div>Effective Time: 20141007</div>
</div>
</div>Â <div class="DistributorName">Galena Biopharma, Inc.</div></p>
</body></html>
